2359 Stock Overview
An investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
WuXi AppTec Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥46.05 |
| 52 Week High | CN¥95.30 |
| 52 Week Low | CN¥27.50 |
| Beta | 0.81 |
| 11 Month Change | -11.36% |
| 3 Month Change | 46.66% |
| 1 Year Change | -50.43% |
| 33 Year Change | -72.46% |
| 5 Year Change | -14.84% |
| Change since IPO | 59.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2359 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -8.9% | -4.1% | 1.6% |
| 1Y | -50.4% | -57.6% | 10.1% |
Return vs Industry: 2359 exceeded the Hong Kong Life Sciences industry which returned -57.6% over the past year.
Return vs Market: 2359 underperformed the Hong Kong Market which returned 10.1% over the past year.
Price Volatility
| 2359 volatility | |
|---|---|
| 2359 Average Weekly Movement | 13.4% |
| Life Sciences Industry Average Movement | 12.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2359's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2359's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 38,134 | Ge Li | www.wuxiapptec.com |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
WuXi AppTec Co., Ltd. Fundamentals Summary
| 2359 fundamental statistics | |
|---|---|
| Market cap | HK$151.11b |
| Earnings (TTM) | HK$8.66b |
| Revenue (TTM) | HK$41.35b |
17.8x
P/E Ratio3.7x
P/S RatioIs 2359 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2359 income statement (TTM) | |
|---|---|
| Revenue | CN¥38.50b |
| Cost of Revenue | CN¥22.86b |
| Gross Profit | CN¥15.64b |
| Other Expenses | CN¥7.57b |
| Earnings | CN¥8.06b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.79 |
| Gross Margin | 40.61% |
| Net Profit Margin | 20.94% |
| Debt/Equity Ratio | 10.1% |
How did 2359 perform over the long term?
See historical performance and comparison